
LENZ Stock Forecast & Price Target
LENZ Analyst Ratings
Bulls say
LENZ Therapeutics is positioned for success with the launch of VIZZ, a novel non-pilocarpine option for presbyopia patients, supported by a robust sales force and direct-to-consumer marketing efforts. Additionally, the recent exclusive commercial partnerships and ongoing development of the pipeline bode well for future growth and expansion. With expected peak penetration and continued commercial validation, LENZ Therapeutics has a strong potential for increased revenue and a favorable outlook for investors.
Bears say
LENZ Therapeutics is expected to have a successful initial launch of its product, VIZZ, which will lead to revenue growth over the upcoming quarters. However, there are also risks to the investment thesis, such as the potential for lower than expected commercial revenue or failure to secure necessary funding for operations. With a $38 price target, the company's valuation appears to be in line with other early commercial-stage biopharmaceutical companies, but investors should be cautious of potential risks when considering an investment.
This aggregate rating is based on analysts' research of LENZ Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LENZ Analyst Forecast & Price Prediction
Start investing in LENZ
Order type
Buy in
Order amount
Est. shares
0 shares